建议英格兰和威尔士采用新的两个月一次的艾滋病毒预防注射,即Cabotegravir,以帮助到2030年结束新的艾滋病毒病例。 A new two-monthly HIV prevention injection, cabotegravir, is recommended for NHS use in England and Wales to help end new HIV cases by 2030.

建议英格兰和威尔士在国民保健体系中使用长效可注射的预防艾滋病毒药物Cabotegravir(Apretude),为每日口服PREP提供两个月的替代药物。 A long-acting injectable HIV prevention drug, cabotegravir (Apretude), has been recommended for use on the NHS in England and Wales, offering a two-monthly alternative to daily oral PrEP. 治疗对象是感染艾滋病毒高风险的成人和青少年,他们由于医疗、生活方式或社会挑战而面临每日服用药片的障碍。 The treatment is for adults and adolescents at high risk of HIV who face barriers to daily pills due to medical, lifestyle, or social challenges. 经国家统计和普查局批准,该服务将通过性健康诊所提供,预计将在几个月内推出。 Approved by NICE, it will be available through sexual health clinics, with rollout expected within months. NHS获得了药品折扣,清单价格约为每年7 000英镑。 The NHS secured a discount on the drug, which has a list price of about £7,000 per year. 官方表示可以帮助英国实现到2030年结束新的艾滋病毒传播的目标。 Officials say it could help the UK reach its goal of ending new HIV transmissions by 2030. 虽然英格兰的PREP使用率在2024年上升到111 000人,但差距依然存在,特别是黑人非洲异性恋男子和妇女之间。 While PrEP use in England rose to 111,000 people in 2024, disparities persist, especially among Black African heterosexual men and women. 倡导者敦促在诊所之外迅速扩展,以改善公平。 Advocates urge rapid expansion beyond clinics to improve equity. 注射必须采用更安全的性行为。 The injection must be used with safer sex practices. 早期研究建议,未来年度选择方案可能是可能的。 Early research suggests future annual options may be possible.